Celyad Oncology S.A.
CYAD
Classifica tra le azioni
#31624
Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to... Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing chimeric antigen receptor T (CAR-T) cell therapies specifically for oncology. Its most advanced therapeutic programs include several candidates undergoing clinical trials. CYAD-101 is an allogeneic CAR-T treatment currently in a Phase 1b study targeting metastatic colorectal cancer. Another allogeneic candidate, CYAD-211, utilizes short hairpin RNA (shRNA) technology and is being evaluated in a Phase 1 trial for patients with relapsed or refractory multiple myeloma. Furthermore, CYAD-02, an autologous CAR-T therapy, is progressing through a Phase 1 study to address relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. In its preclinical pipeline, the company is developing CYAD-203. This is a non-gene-edited allogeneic CAR-T candidate designed to co-express interleukin-18 (IL-18) cytokine with natural killer group 2D ligands (NKG2D), intended for the treatment of various solid tumors. Celyad Oncology holds a licensing agreement with Novartis International AG, granting rights to U.S. patents concerning allogeneic CAR-T cells. Additionally, it has established research and development collaborations and licensing agreements with Horizon Discovery Group plc, leveraging their shRNA technology to create an alternative non-gene-edited allogeneic platform. Established in 2004, the company was initially known as Celyad SA before rebranding to Celyad Oncology SA in June 2020. Its headquarters are situated in Mont-Saint-Guibert, Belgium.
Prezzo delle azioni
$0.25502336
Ultima sincronizzazione: 2026-10-16
Capitalizzazione di mercato
$12.05M
Variazione (1 giorno)
0.47%
Variazione (1 anno)
-45.74%
Paese
BE
Scambia Celyad Oncology S.A. (CYAD)
Categoria
Healthcare
Capitalizzazione di mercato di Celyad Oncology S.A.(CYAD)
Capitalizzazione di mercato: $12.05M
A partire dal October 2026, Celyad Oncology S.A. ha una capitalizzazione di mercato pari a $12.05M. Questo rende Celyad Oncology S.A. la 31624th azienda più preziosa al mondo per capitalizzazione di mercato secondo i nostri dati. La capitalizzazione di mercato è il valore totale delle azioni in circolazione di una società quotata e viene comunemente utilizzata per misurarne il valore.
Storia della capitalizzazione di mercato di Celyad Oncology S.A. dal 2015 al 2026
CYAD in paragone con la classifica dei più popolari stocks
